Attorney General Bonta Co-Leads Lawsuit Against Trump Administration for Unlawfully Terminating and Withholding Medical and Public Health Research Grants

In 2024, NIH awarded $5.15 billion in grants and contracts that directly supported 55,324 jobs and $13.81 billion in economic activity in California

OAKLAND — California Attorney General Rob Bonta today co-led 16 attorneys general in filing a lawsuit against the Trump Administration, the Department of Health and Human Services, and the National Institutes of Health (NIH) for failing to disperse grant funds and for unlawfully terminating existing grants for medical and public health research institutions across the country. Despite Congressional direction, the NIH has drastically reduced its funding to advance the United States' understanding of human disease and potential treatments. As a result, California universities have begun curtailing biomedical research and delaying the hiring of new staff and students who depend on NIH funding.

“In their unlawful withholding and terminating of medical and public health research grants, the Trump Administration is upending not only the critical work being done today, but the promise of progress for future generations,” said Attorney General Rob Bonta. “Through research, we save lives, improve public wellbeing and create new economic opportunities that support a vibrant economy. Let me be clear: in California, NIH funding creates over 50,000 jobs and billions of dollars in economic activity. Over the decades, this funding has brought humanity the eradication of polio, discovery of the gene that causes breast and ovarian cancer, and the transformation of HIV from a fatal disease into one people can live with. Gutting NIH funding is a deep loss to innovation and progress built upon for decades — and it’s illegal. My office is proudly leading the charge to demand that the Trump Administration immediately restore funding to the important work being done in labs, schools, and hospitals across the nation.”

"The American research enterprise is the most successful, important, and impactful in the world,” said UC President Michael V. Drake, M.D. “We must continue to do all we can to develop treatments and cures for the serious medical conditions that threaten us all."

“We applaud the attorney general for filing this lawsuit. NIH funding is vital to the CSU’s ability to offer immersive student learning and discovery through distinctive research programs that directly benefit the health of all Americans,” said Ganesh Raman, Assistant Vice Chancellor for Research at the California State University. “These grants not only support research, but they also provide stipend and other funding that impact hundreds of CSU students, staff and faculty who engage in meaningful, and career-defining work. Terminating these federal grants will cause irreparable harm, undermine scientific progress and our collective capacity to innovate and lead California’s economy.”

NIH is the federal agency responsible for biomedical and public health research. Over 80% of Congressional funding supports NIH research and training at external labs, schools, and hospitals. It is estimated that every $1 invested in NIH research generates $2.56 of economic activity.

Over the years, NIH-supported research has had a profound impact on the health and wellbeing of the American people. NIH scientists pioneered the rubella vaccine, eradicating a disease that, in the 1960s, killed thousands of babies and left thousands more with lifelong disabilities. NIH studies led to the discovery of the BRCA mutation, helping countless Americans reduce their risk of breast and ovarian cancer. NIH research fueled the development of treatments for HIV and AIDS, transforming what used to be a fatal disease into one with a nearly normal life expectancy.   

The termination of NIH funding for research interventions to prevent or treat the spread of diseases like HIV/AIDS, Covid and other virus families of pandemic concern — including emerging diseases such as Dengue, Chikungunya, and Zika — increases the risk of and incidence of these diseases in California. The terminations have specifically targeted some of the most vulnerable Californians, including women experiencing domestic violence, children at risk of suicide, and underserved communities at a higher risk of chronic or infectious diseases.

Yet the Trump Administration has frozen the highly competitive process for approving new NIH grants. The Administration has also terminated existing NIH grants without any reasonable explanations after those grants were funded based on their scientific merit and potential innovative impact and appears to have terminated grants based on the projects' perceived connection to "DEI,” "transgender issues,” "vaccine hesitancy," or other topics disfavored by the Trump Administration. Similarly, training grants directed to increase diversity in the research work force have been pulled from review. NIH claims that these grants “no longer effectuate agency priorities.” 

In today’s lawsuit, the attorneys general argue that the Trump Administration’s actions are arbitrary and capricious. The Trump Administration does not have the authority to unilaterally decline spending congressionally appropriated funds. As such, the attorneys general seek a temporary restraining order to immediately restore grant funding to the states and bar the Administration from unlawfully terminating grants.

In February, Attorney General Bonta filed a lawsuit against the Trump Administration’s unlawful attempt to cut “indirect cost” reimbursements at every research institution throughout the country. Indirect cost reimbursements refer to expenses that are necessary to support research but are not easily linked to a specific research project. 

In bringing today’s lawsuit Attorney General Bonta and the attorneys general of Massachusetts, Maryland, and Washington lead the attorneys general of Arizona, Colorado, Delaware, Hawaii, Minnesota, Nevada, New Jersey, New Mexico, New York, Oregon, Rhode Island, and Wisconsin. 

A copy of the complaint can be found here.